Back to top
more

Adamis Pharmaceuticals Corporation (ADMP)

(Delayed Data from NSDQ)

$0.75 USD

0.75
11,477,532

+0.01 (1.10%)

Updated May 7, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 17% (210 out of 254)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California.

General Information

Adamis Pharmaceuticals Corporation

11682 EL CAMINO REAL SUITE 300

SAN DIEGO, CA 92130

Phone: 858-997-2400

Fax: NA

Web: http://www.adamispharmaceuticals.com

Email: ir@adamispharma.com

Industry Medical - Drugs
Sector Medical
Fiscal Year End December
Last Reported Quarter 3/31/2021
Next EPS Date 5/17/2021

EPS Information

Current Quarter EPS Consensus Estimate -0.06
Current Year EPS Consensus Estimate -0.24
Estimated Long-Term EPS Growth Rate NA
Next EPS Report Date 5/17/2021

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 0.74
52 Week High 2.34
52 Week Low 0.38
Beta 1.30
20 Day Moving Average 6,850,529.50
Target Price Consensus 0.00

ADMP

% Price Change
4 Week -22.27
12 Week -53.05
YTD 51.97
% Price Change Relative to S&P 500
4 Week -24.20
12 Week -56.23
YTD 35.85
Share Information
Shares Outstanding (millions) 148.89
Market Capitalization (millions) 109.76
Short Ratio NA
Last Split Date 12/13/2013
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year -100.00%
vs. Previous Quarter -60.00%
   
Sales Growth
vs. Previous Year -34.35%
vs. Previous Quarter -15.44%
   
Price Ratios
Price/Book 28.28
Price/Cash Flow NA
Price / Sales 6.64
ROE
3/31/21 NA
12/31/20 -176.31
9/30/20 -102.15
ROA
3/31/21 NA
12/31/20 -96.27
9/30/20 -67.47
Current Ratio
3/31/21 NA
12/31/20 0.63
9/30/20 1.32
Quick Ratio
3/31/21 NA
12/31/20 0.47
9/30/20 1.16
Operating Margin
3/31/21 NA
12/31/20 -232.64
9/30/20 -161.76
Net Margin
3/31/21 NA
12/31/20 -298.85
9/30/20 -188.31
Pre-Tax Margin
3/31/21 NA
12/31/20 -298.84
9/30/20 -178.52
Book Value
3/31/21 NA
12/31/20 0.03
9/30/20 0.30
Inventory Turnover
3/31/21 NA
12/31/20 6.06
9/30/20 7.39
Debt-to-Equity
3/31/21 NA
12/31/20 0.25
9/30/20 0.05
Debt to Capital
3/31/21 NA
12/31/20 20.30
9/30/20 4.94